PAMIDRONATE DISODIUM
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PAMIDRONATE DISODIUM by Hikma is clinical pharmacology the principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Approved for moderate, severe hypercalcemia associated with malignancy, with and 1 more indications. First approved in 2002.
Drug data last refreshed 7h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pamidronate disodium is a bisphosphonate administered intravenously that inhibits bone resorption by adsorbing to hydroxyapatite crystals and blocking osteoclast activity. It is indicated for moderate to severe hypercalcemia associated with malignancy, with or without bone metastases. The drug works by suppressing accelerated bone resorption induced by tumor-driven osteoclast hyperactivity.
LOE Approaching
Product is nearing loss of exclusivity with 30% competitive pressure; commercial teams face declining market size and consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium…
Worked on PAMIDRONATE DISODIUM at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.